Omthera Pharmaceuticals, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2013 | $18 M | No. 3 | $10 to $50 million | debt, options | SEC | |
| Feb 2011 | $39 M | No. 2 | $10 to $50 million | equity | SEC | |
| Nov 2009 | $2 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Omthera Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2013).
SEC Form D · Feb 2013
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2013
That is all the official record says: Omthera Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bernardus N. M. Machielse | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2013) | SEC Form 3 |
| Christian S. Schade | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2013) | SEC Form 3 |
| Gerald Wisler | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2013) | SEC Form 3 |
| Michael H. Davidson | Person | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| NEA 13 GP, Ltd | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| NEA Partners 13, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| New Enterprise Associates 13 LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sofinnova Capital VI Fcpr | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Sofinnova Partners SAS | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 13 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Bernardus Machielse | Executive officer | Feb 2013 |
| Christian Schade | Executive officer | Feb 2013 |
| Gerald Wisler | Executive officer | Feb 2013 |
| Michael Davidson | Executive officer | Feb 2013 |
| Douglas Carr | Executive officer | Mar 2011 |
| David Mott | Director | Feb 2013 |
| George Horner | Director | Feb 2013 |
| Gerald Wisler | Director | Feb 2013 |
| Graziano Seghezzi | Director | Feb 2013 |